STEMEDICA NEWS
STEMEDICA ANNOUNCES THE APPOINTMENT OF DR. CÉSAR AMESCUA GARCIA AS MEDICAL AND REGULATORY AFFAIRS DIRECTOR – LATIN AMERICA
Dr. Amescua will be responsible for liaison with regulatory agencies in Latin America regarding approvals of Stemedica’s stem cell products for use in clinical (human) trials which follow the criteria required by the FDA in the United States.
DR. MAYNARD HOWE, CEO OF STEMEDICA, THE LEADING ALLOGENEIC ADULT STEM CELL MANUFACTURER, JOINS USO BOARD OF GOVERNORS
Dr. Maynard A. Howe, CEO and Vice Chairman of Stemedica, was welcomed as the newest member of the USO Board of Governors during their May Board Meeting held in San Antonio, Texas.
STEMEDICA ANNOUNCES THE APPOINTMENT OF DR. LEV VERKH AS CHIEF REGULATORY AND CLINICAL DEVELOPMENT OFFICER
Stemedica announces the appointment of Lev Verkh, PhD as Chief Regulatory and Clinical Development Officer. Dr. Verkh will be responsible for managing all regulatory activities and clinical trials on behalf of the company.
FDA APPROVES STEMEDICA IND APPLICATION FOR ISCHEMIC STROKE CLINICAL TRIAL
Stemedica announced that the U.S. Food and Drug Administration (FDA) approved its application for an Investigational New Drug (IND) for a clinical trial for ischemic stroke using Stemedica's high potency proprietary allogeneic stem cells (adult human).
STEMEDICA FILES IND APPLICATION WITH FDA FOR TREATMENT OF STROKE WITH ADULT ALLOGENEIC MESENCHYMAL STEM CELLS
Stemedica announced that it has filed an Investigative New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for a clinical trial. The trial will assess the safety, tolerability and efficacy of Stemedica's high potency proprietary allogeneic mesenchymal bone marrow-derived stem cells (adult human) as a treatment for ischemic stroke.
PROMINENT HEALTH CARE EXECUTIVE JOINS STEMEDICA BOARD OF DIRECTORS
Anthony M. Marlon, MD was elected to the Stemedica Cell Technologies, Inc. (“Stemedica”) Board of Directors at the Company’s November 20th Board Meeting.
STEMEDICA PRESIDENT INVITED TO LECTURE AT THE UNIVERSITY OF OXFORD
Nikolai Tankovich, MD, Ph.D., President and Chief Medical Officer of Stemedica Cell Technologies, Inc. was invited to lecture at a multi-disciplinary seminar at the Centre for Science and Society at Trinity College, a constituent college of the University of Oxford, England.
STEMEDICA COMPLETES MEETING WITH THE FDA
Stemedica announced that it completed its pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding a proposed IND (Investigative New Drug) to evaluate the safety and efficacy of Stemedica's high potency proprietary allogeneic mesenchymal bone marrow-derived stem cells (adult human) as a treatment for ischemic stroke.
STEMEDICA’S PRESIDENT DELIVERS KEYNOTE ADDRESS AT SWISS-RUSSIAN FORUM
Dr. Nikolai Tankovich, President of Stemedica, delivered the keynote speech at the Crossing Visions Summit held in Moscow from September 14th – 16th. His presentation at a forum of top Russian and Swiss political, economic and business leaders featured advances in stem cell technology.
DRIVEN BY 30 YEARS OF STEM CELL RESEARCH & SCIENTIFIC ADVANCEMENT
Stemedica's adult stem cell technology is based on thirty years of research and clinical experience conducted by researchers and clinicians in the former Soviet Union, Europe and the United States. The technology and scientific know-how advanced by these researchers and clinicians has either been acquired, or developed internally, by Stemedica.
To further substantiate these discoveries, and to continue to advance the science achieved by these leaders, Stemedica has established a laboratory and manufacturing facility in San Diego, California designed from the ground up to be fully cGMP (Current Good Manufacturing Practices) compliant. Additional laboratory and manufacturing facilities have been established in Moscow, Russia and in Seoul, Korea.
Stemedica has built an experienced team of international and domestic scientists and medical professionals that have been involved for the past four years in extensive research and stem cell product development including; a) confirming the safety, reliability and efficacy of the Company's science and technology; b) advancing the Company's protocols for isolating, expanding, processing, manufacturing and master banking of stem cells; and, c) refining Stemedica's methodologies and protocols used in clinical applications.
Stemedica continues to advance its adult stem cell technology for current pre-clinical and future clinical studies in the United States and for on-going pre-clinical and clinical studies internationally.
ABOUT ADULT STEM CELLS
What are adult stem cells?
Adult stem cells are cells which have not completely differentiated. They are found in all tissues of the human body. Adult stem cells, also known as somatic stem cells, have the potential to transform themselves into practically all other cell types. Adult stem cells are at the heart of Stemedica's technology and research.